Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.48%
As of Friday, October 23, Verrica Pharmaceuticals Inc.’s VRCA share price has dipped by 5.48%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Stock Evaluator: Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. VRCA
$3.42
-0.06
-1.72%
October 29, 2026 4:00:00 PM
EST
Volume: 29,690
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Commentary & Analysis
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 8.13%
As of Thursday, October 22, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 8.13%, which has investors questioning if this is right time to sell.Michael Rose
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 10.74%
As of Thursday, October 22, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 10.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 9.23%
As of Tuesday, October 13, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 9.23%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.74%
As of Thursday, September 17, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $58.9 | $496.7 | 18% |
|
| Shares Out (Mil) | 21.3 | 42.8 | 32% |
|
| Institutional Ownership | 88.3% | 81.2% | 56% |
|
| Float (Mil) | 12.4 | 44.5 | 22% |
|
| Beta | 1.50 | 0.72 | 82% |
|
| Avg Daily Volume (000s) | 56 | 268 | 31% |
|
| Price Change (52-week) |
(5.3%) | 56.1% | 47% |
|
| Growth | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | 16.0% | (2.0%) | 66% |
|
| EPS (5yr) | 37.1% | 15.0% | 87 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.8%) | (15.1%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.493) | ($1.878) | ($1.240) | |
| Month Ago EPS | ($0.520) | ($1.965) | ($1.478) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.427) | ($1.733) | ($1.243) | |
| Year/Year Chg | (20.5%) | 11.9% | (50.7%) | |
| Financials | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $30 | $392 | 16% |
|
| Net Income (TTM) (Mil) | ($31) | ($11) | 20% |
|
| EPS (TTM) | ($1.883) | ($0.700) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($7) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 17% |
|
| Enterprise Value (Q1) (Mil) | $67 | $493 | 18% |
|
| Valuation | VRCA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.72 | 2.23 | 93% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.7% | 67.8% | 46% |
|
| Net Margin | (102.8%) | 3.3% | 8% |
|
| ROA | (83.0%) | (22.0%) | 7% |
|
| ROE | 473.3% | (20.6%) | 99% |
|
| Liabilities to Assets | 88.0% | 32.0% | 82% |
|
| F-Score | 6 | 3 | 68% |
|
Verrica Pharmaceuticals Inc. did not pass any screens on 10/29/2026.
